Slamon DJ, Neven P, Chia S, et al. - Since ribociclib plus fulvestrant indicated a greater advantage with regard to progression-free survival than fulvestrant alone in postmenopausal patients with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer, researchers present the outcomes of a protocol-specified second interim analysis of overall survival. Individuals were allocated randomly in a 2:1 ratio to receive either ribociclib or placebo in addition to fulvestrant as first-line or second-line treatment. They assessed survival using a stratified log-rank test and summarized with the use of Kaplan–Meier methods. This study was based on 275 deaths: 167 among 484 patients (34.5%) getting ribociclib and 108 among 242 (44.6%) taking placebo. In individuals with hormone-receptor-positive, HER2-negative advanced breast cancer, ribociclib plus fulvestrant revealed a significant overall survival advantage over placebo plus fulvestrant.